Literature DB >> 12393548

Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.

Evangelos Andreakos1, Clive Smith, Claudia Monaco, Fionula M Brennan, Brian M Foxwell, Marc Feldmann.   

Abstract

Although dendritic cells (DCs) are the most potent antigen-presenting cells involved in numerous physiologic and pathologic processes, little is known about the signaling pathways that regulate DC activation and antigen-presenting function. Recently, we demonstrated that nuclear factor (NF)-kappaB activation is central to that process, as overexpression of IkappaBalpha blocks the allogeneic mixed lymphocyte reaction (MLR), an in vitro model of T-cell activation. In this study, we investigated the role of 2 putative NF-kappaB-inducing components, NF-kappaB-inducing kinase (NIK), and IkappaB kinase 2 (IKK2). Using an adenoviral gene transfer method to efficiently express dominant-negative (dn) forms of these molecules in monocyte-derived DCs, we found that IKK2dn but not NIKdn inhibited the allogeneic MLR. When DCs were fixed, this inhibitory effect of IKK2dn was lost, suggesting that IKK2 is involved in T-cell-derived signals that enhance DC antigen presentation during the allogeneic MLR period and does not have an effect on viability or differentiation state of DCs prior to coculture with T cells. One such signal is likely to be CD40 ligand (CD40L), as IKK2dn blocked CD40L but not lipopolysaccharide (LPS)-induced NF-kappaB activation, cytokine production, and up-regulation of costimulatory molecules and HLA-DR in DCs. In summary, our results demonstrate that IKK2 is essential for DC activation induced by CD40L or contact with allogeneic T cells, but not by LPS, whereas NIK is not required for any of these signals. In addition, our results support IKK2 as a potential therapeutic target for the down-regulation of unwanted immune responses that may occur during transplantation or autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393548     DOI: 10.1182/blood-2002-06-1835

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Authors:  B Foxwell; E Andreakos; F Brennan; M Feldmann; C Smith; M Conron
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

3.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

4.  The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis.

Authors:  Sandra M Sacre; Evangelos Andreakos; Serafim Kiriakidis; Parisa Amjadi; Anna Lundberg; Grey Giddins; Marc Feldmann; Fionula Brennan; Brian M Foxwell
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 5.  NF-κB in immunobiology.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

6.  Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.

Authors:  Sumit Bhattacharyya; Alip Borthakur; Pradeep K Dudeja; Joanne K Tobacman
Journal:  Exp Cell Res       Date:  2010-05-11       Impact factor: 3.905

7.  Distinct regulation of CD40-mediated interleukin-6 and interleukin-12 productions via mitogen-activated protein kinase and nuclear factor kappaB-inducing kinase in mature dendritic cells.

Authors:  Yoshiki Yanagawa; Kazunori Onoé
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

8.  Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.

Authors:  Anand K Katakam; Hans Brightbill; Christian Franci; Chung Kung; Victor Nunez; Charles Jones; Ivan Peng; Surinder Jeet; Lawren C Wu; Ira Mellman; Lélia Delamarre; Cary D Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-11       Impact factor: 11.205

9.  NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses.

Authors:  Janin Hofmann; Florian Mair; Melanie Greter; Marc Schmidt-Supprian; Burkhard Becher
Journal:  J Exp Med       Date:  2011-08-01       Impact factor: 14.307

10.  Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.

Authors:  Adnan Khan; Hongmei Fu; Lee Aun Tan; Jennifer E Harper; Sven C Beutelspacher; Daniel F P Larkin; Giovanna Lombardi; Myra O McClure; Andrew J T George
Journal:  Eur J Immunol       Date:  2013-01-18       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.